Abbott Laboratories Revenue Growth: 4.10%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ABT Revenue Growth Rankings
| Overall | 40th percentile | 2642 of 4424 |
| Sector | 39th percentile | 282 of 464 in Healthcare |
| Industry | 44th percentile | 11 of 20 in Drug Manufacturers - Major |
ABT Revenue Growth Range, Past 5 Years
| Minimum | -45.24% | Dec 2002 |
| Maximum | 77.71% | Dec 2003 |
| Average | 9.62% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ABT related companies
ABT News
A Forward Look, the Year Ahead - Featured Research on Acorda Therapeutics Inc and Abbott Laboratories
Feb 09, 9:00AM Marketwire
Feb 09, 9:00AM Marketwire
YCHARTS DIVIDEND DAILY: Some “Non-Royalty” Dividends Beat the Aristocrats http://stks.co/2J5E $GE $ITW $ABT $MRK $CVX $XOM
about 4 days ago by ycharts
about 4 days ago by ycharts
Abbott Creates New Similac SimplySmart™ Baby Bottle with Innovative Features
Feb 08, 9:00AM PR Newswire
Feb 08, 9:00AM PR Newswire
$ABT Insider Sale: $2.8M of stock sold by Edward Michael (Executive Vice President) on February 3, 2012 http://stks.co/2IH1
about 5 days ago by MarketBrief
about 5 days ago by MarketBrief
Remembrance of Buy List Stocks Past | via @EddyElfenbein http://stks.co/2I75 $GILD $LUK $JEF $DLX $BDX $ABT
about 5 days ago by STNet
about 5 days ago by STNet
Another Reason to Worry About Profits: Uncle Sam is Propping Them Up With Tax Breaks http://stks.co/2Hlw $MSFT $KO $ABT
about 5 days ago by ycharts
about 5 days ago by ycharts
$ABT is looking good here @ $55.80. MACD, STO, RSI all pointing higher. no pos.
about 5 days ago by stubbybrown
about 5 days ago by stubbybrown
$ABT Nice bounce off of support, channel top around $58 http://chart.ly/yacrf6f
about 6 days ago by optionmaster
about 6 days ago by optionmaster
Just home from a morning appt. Grabbed a first position in $ABT at $55.19
about 6 days ago by AffluenzaVirus
about 6 days ago by AffluenzaVirus
$ABT. Low PE, low BETA and good financials make for good timliness & safety!
about 8 days ago by InvestProfits
about 8 days ago by InvestProfits
$ABT Insider Sale: $1.2M of stock sold by Stephen Fussell (Senior Vice President) on February 1, 2012 http://stks.co/2F7l
about 9 days ago by MarketBrief
about 9 days ago by MarketBrief
Are Bank Shareholders Passive Patsies? ROA Numbers Suggest Breakups Long Overdue http://stks.co/2Ahf $JPM $BAC $C $WGC $USB $KFT $ABT
about 12 days ago by ycharts
about 12 days ago by ycharts
$ABT http://stks.co/28T6 watch this name closely. interesting plays both on the upside or downside
about 15 days ago by MCM
about 15 days ago by MCM
Updated. Putting in a LOT of energy to hold this 55 level. 50d MA test SOON, play the reaction. $ABT http://chart.ly/frrglcp
about 15 days ago by 1nvestor
about 15 days ago by 1nvestor
10 week support looking tenuous here. Sell stop to short below that line at 54.55 $ABT http://chart.ly/so5ftg8
about 16 days ago by chartsmart
about 16 days ago by chartsmart
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABT | 55.11 | -0.15 | -0.27% | 85.85B |
| PTIX | 1.99 | 0.11 | 5.85% | 22.13M |
| ELON | 5.51 | -0.64 | -10.37% | 234.23M |
| OFG | 11.84 | -0.07 | -0.59% | 521.08M |
| XOM | 83.80 | -1.08 | -1.27% | 401.67B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| CTB | 15.93 | -0.62 | -3.75% | 991.80M |
| SOHU | 50.93 | 0.03 | 0.06% | 1.94B |
| MENT | 14.49 | -0.25 | -1.70% | 1.59B |
| NOK | 4.96 | -0.11 | -2.17% | 18.58B |
